Pharmafile Logo

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring for children with the disease. It also puts a considerable burden on healthcare resources. AD affects up to 20% of children and around 3% of adults worldwide and its prevalence is still increasing, especially in some lower income countries in Asia and Latin America. The majority of patients start to experience symptoms before they reach 5 years of age and often suffer from asthma or other allergies. Severity varies widely – some people might just suffer from a light rash on a few areas of the body and might get better as they get older, whilst others can suffer from very dry, bleeding and sore skin all over, with regular painful flare-ups, which continue into adulthood. In the US, physicians typically use the Body Surface Index to assess severity of the disease. Around 65% of patients in the US are recognised as suffering from moderate-severe eczema. Severe patients can suffer from more than 15 flare-ups per year, lasting two weeks or more…Read the full article: https://bit.ly/2rkI7jc

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

A researcher’s guide to Key Driver Analysis

Research Manager Kayleigh Simpson explores how Key Driver Analysis can be used to answer key business

Research Partnership sends a cheque for $10,000 to Forever Angels

Helping them in their mission of caring for and improving the lives of orphans and abandoned infants in Tanzania

Pharma Market Research Conference, 2018

We are delighted to be presenting and exhibiting at PMRC, 14-15 February in Newark, NJ.

Out of the shadows: Mental health in the Asia Pacific region

In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia

Research Partnership has published a new patient Living with Atopic Dermatitis (US) report

Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. The report consists of 45-minute quantitative and 30-minute qualitative...

Research Partnership has published a new patient Living with Psoriasis (EU) report

Living with Psoriasis is a report based on a new study conducted in the main 5EU markets and Belgium and the Netherlands (reports can be purchased for either 5EU or 7EU)....

New opportunities in emerging markets

Published in Pharma Exec January 2018 by Rachel Howard

Webinar: Portfolio tracking for success

Thursday 18th January 2018 11:00 EST / 16:00 GMT / 17:00 CEST

20 questions: Round-up video

As it's our 20th year anniversary, we invited our employees to play our version of 20 questions throughout the year - this month we have created a final round-up video showcasing some...

Patient centricity: Reality or rhetoric?

Everybody is talking about patient centricity, but what does it mean for those involved in market research, insights and business intelligence?